VALN Valneva SE - ADRs

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:VLA.

$27.27  0.00 (0.00%)
As of 06/27/2022 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  
IPO date:  05/06/2021
Outstanding shares:  53,581,162
Average volume:  55,013
Market cap:   $1,684,591,733
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      4581619
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   9.90
PS ratio:   14.54
Return on equity:   -162.39%
Net income %:   -113.86%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy